| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| AERIE PHARMACEUTICALS INC | Chief R&D Officer | Common Stock | 30.7K | $469K | $15.25 | Feb 4, 2022 | Direct |
| Revance Therapeutics, Inc. | CMO & Global Therapeutics Lead | Common Stock | 105K | $438K | $4.17 | Nov 18, 2024 | Direct |
| KIORA PHARMACEUTICALS INC | Director | Stock Option (right to buy) | 1.78K | Jul 1, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| RVNC | Revance Therapeutics, Inc. | Nov 18, 2024 | 1 | -$16.3K | 4 | Nov 19, 2024 | CMO & Global Therapeutics Lead |
| KPRX | KIORA PHARMACEUTICALS INC | Jul 1, 2024 | 1 | $0 | 4 | Jul 3, 2024 | Director |
| RVNC | Revance Therapeutics, Inc. | Feb 27, 2024 | 0 | $0 | 3 | Feb 29, 2024 | CMO & Global Therapeutics Lead |
| KPRX | KIORA PHARMACEUTICALS INC | Sep 29, 2023 | 1 | $0 | 4 | Oct 3, 2023 | Director |
| KPRX | KIORA PHARMACEUTICALS INC | Mar 3, 2023 | 1 | $0 | 4 | Mar 7, 2023 | Director |
| AERI | AERIE PHARMACEUTICALS INC | Feb 4, 2022 | 1 | -$6.54K | 4 | Feb 8, 2022 | Chief R&D Officer |
| KPRX | KIORA PHARMACEUTICALS INC | Feb 1, 2022 | 2 | $0 | 4 | Feb 3, 2022 | Director |
| KPRX | KIORA PHARMACEUTICALS INC | Dec 13, 2021 | 0 | $0 | 3 | Dec 23, 2021 | Director |
| AERI | AERIE PHARMACEUTICALS INC | Nov 11, 2021 | 1 | -$26.1K | 4 | Nov 15, 2021 | Chief R&D Officer |